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http://www.epigeneticsandchromatin.com/content/6/1/11RESEARCH Open AccessThe histone deacetylase inhibitor sodium
valproate causes limited transcriptional change in
mouse embryonic stem cells but selectively
overrides Polycomb-mediated Hoxb silencing
Elsa Boudadi1, Hannah Stower1, John A Halsall1, Charlotte E Rutledge1, Martin Leeb2, Anton Wutz2, Laura P O’Neill1,
Karl P Nightingale1 and Bryan M Turner1*Abstract
Background: Histone deacetylase inhibitors (HDACi) cause histone hyperacetylation and H3K4 hypermethylation in
various cell types. They find clinical application as anti-epileptics and chemotherapeutic agents, but the pathways
through which they operate remain unclear. Surprisingly, changes in gene expression caused by HDACi are often
limited in extent and can be positive or negative. Here we have explored the ability of the clinically important
HDACi valproic acid (VPA) to alter histone modification and gene expression, both globally and at specific genes, in
mouse embryonic stem (ES) cells.
Results: Microarray expression analysis of ES cells exposed to VPA (1 mM, 8 h), showed that only 2.4% of genes
showed a significant, >1.5-fold transcriptional change. Of these, 33% were down-regulated. There was no
correlation between gene expression and VPA-induced changes in histone acetylation or H3K4 methylation at gene
promoters, which were usually minimal. In contrast, all Hoxb genes showed increased levels of H3K9ac after
exposure to VPA, but much less change in other modifications showing bulk increases. VPA-induced changes were
lost within 24 h of inhibitor removal. VPA significantly increased the low transcription of Hoxb4 and Hoxb7, but not
other Hoxb genes. Expression of Hoxb genes increased in ES cells lacking functional Polycomb silencing complexes
PRC1 and PRC2. Surprisingly, VPA caused no further increase in Hoxb transcription in these cells, except for Hoxb1,
whose expression increased several fold. Retinoic acid (RA) increased transcription of all Hoxb genes in
differentiating ES cells within 24 h, but thereafter transcription remained the same, increased progressively or fell
progressively in a locus-specific manner.
Conclusions: Hoxb genes in ES cells are unusual in being sensitive to VPA, with effects on both cluster-wide and
locus-specific processes. VPA increases H3K9ac at all Hoxb loci but significantly overrides PRC-mediated silencing
only at Hoxb4 and Hoxb7. Hoxb1 is the only Hoxb gene that is further up-regulated by VPA in PRC-deficient cells.
Our results demonstrate that VPA can exert both cluster-wide and locus-specific effects on Hoxb regulation.
Keywords: Hoxb genes, Valproic acid, Histone deacetylase, Polycomb repression, Mouse embryonic stem cells,
Histone modification, Microarray expression analysis, Retinoic acid, Transcriptional activation* Correspondence: b.m.turner@bham.ac.uk
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Histone deacetylase inhibitors (HDACi) have long been
known to cause global histone hyperacetylation, often
accompanied by increased H3K4 methylation, in a
variety of model systems ([1] and references therein).
Two structurally unrelated HDACi, suberoylanilide
hydroxamic acid (SAHA) and depsipeptide (a bicyclic
peptide) are remarkably effective against cutaneous T-cell
lymphoma (CTCL) [2,3] and have been Food and Drug
Administration (FDA) approved for treatment of this
cancer (Additional file 1: Table S1). HDACi have great
potential as chemotherapeutic agents, prompting searches
for new HDACi and a growing number of trials against
various cancers [4,5]. A major barrier to improving the
clinical effectiveness of HDACi is that their mechanisms
of action are varied and complex, and generally not
well understood (discussed in [6]). There are at least
six different structural classes of HDACi, four of which
are in clinical trials (Additional file 1: Table S1). All
exert multiple effects on cell function, including induction
of differentiation, cell cycle disruption and apoptotic death
[5,6]. The situation is further complicated by the fact that
there are 18 different histone deacetylases (HDACs) in
human cells, split into four classes [5,7]. Eleven of these
enzymes, classes I, IIa, IIb and IV, have a very similar
catalytic site, but differ in subtle ways in their sensitivities
to HDACi (Additional file 1: Table S1) [6]. Class III
enzymes, the sirtuins, are NAD-dependent and are
insensitive to all classes of HDACi in clinical use [8].
In addition, HDACs, despite their name, act on a variety of
proteins in addition to histones [9], including transcription
factors, enzymes and HDACs themselves [10]. They usually
operate in vivo as part of multi-protein complexes, the
composition of which can influence their catalytic activity,
their location within the cell and their targeting to specific
genes [7,9].
Valproic acid (VPA) is a branched, short-chain fatty
acid that inhibits class I and IIa HDACs, most likely
through binding to the catalytic site [11]. VPA has been
used clinically for many years as an anti-epileptic agent
and mood stabiliser, usually as the sodium salt [11,12].
Because it is well tolerated and has been shown to
induce differentiation and apoptosis of carcinoma cells,
it has recently been tested in clinical trials as a potential
chemotherapeutic agent for a variety of cancers [4,13]. One
long-appreciated side effect of VPA is its teratogenicity,
causing problems for those women who must depend on it
during pregnancy because alternative drugs are ineffective
or unavailable [14,15]. Teratogenic effects include
musculoskeletal, neurological and behavioural aberrations,
leading to identification of a distinctive valproate syndrome
[15-17]. VPA acts on class I and IIa HDACs, which
collectively deacetylate a variety of nuclear and cytoplasmic
proteins, so its effects are inevitably pleiotropic. Forexample, VPA induces oxidative stress, with increased
levels of reactive oxygen species, and anti-oxidants can
alleviate some of its teratogenic effects [18,19].
Surprisingly, global changes in histone modification
induced by HDACi are usually not accompanied by changed
levels at individual genes, as measured by chromatin
immunoprecipitation (ChIP). In fact, butyrate has been
reported to cause an unexpected decrease in histone
acetylation at some transcription start sites in HepG2 and
HT29 cells, with associated down-regulation of transcription
[20]. A wide ranging ChIP-seq study of quiescent human
T-cells showed that a combination of butyrate and
Trichostatin A (TSA) at high concentrations induced
acetylation primarily at the promoters of active genes
and of the small proportion of silent genes that showed
high levels of H3K4 methylation [21]. In human
lymphoblastoid cells we found that only a small proportion
of genes showed altered transcription after treatment with
VPA. Of these, almost as many were down-regulated as
were up-regulated [22], consistent with early findings of a
surprising lack of transcriptional stimulation by HDACi
[23]. Nor did we find any consistent increase in histone
acetylation or H3K4 methylation at selected promoter
regions, leading to the suggestion that many genes are
sheltered from the global effects of HDACi [22].
The complex relationship between the histone modifica-
tions induced by HDACi and the transcription of individual
genes reflects the general uncertainty surrounding the
role of histone modifications in transcriptional control.
The recent achievements in genome-wide mapping of
chromatin marks have confirmed that some histone
modifications are usually associated with transcriptionally
active, or potentially active, genes (for example, H3K9ac,
H3K4me3), while others are typical of silent genes (for
example, H3K9me2/3, H3K27me3) [24,25]. However, such
data cannot establish the cause-effect relationship between
histone modification and gene activity. It is important to
establish for particular loci in particular developmental
contexts, whether a histone modification can by itself drive
a change in chromatin function, whether the modification
is part of a chain of events by which chromatin transitions
from one functional state to another, or whether the modi-
fication is simply a by-product of other processes and of
no functional consequence in its own right [26,27].
In the experiments reported here, we have tested the
ability of VPA to alter patterns of gene expression in
mouse embryonic stem (ES) cells, looking in detail at its
effects on members of the Hoxb cluster. The Hox
(Homeobox) genes encode highly conserved transcription
factors that act as master regulators of development and
whose mis-expression has been implicated in a variety of
human diseases, including cancer [28,29], and possibly
in the teratogenicity of VPA [15]. In vertebrates, 39 Hox
genes are divided between four clusters (A, B, C and D)
Boudadi et al. Epigenetics & Chromatin 2013, 6:11 Page 3 of 16
http://www.epigeneticsandchromatin.com/content/6/1/11located on different chromosomes. They are silent or
very weakly expressed in the pre-implantation mammalian
embryo and in ES cells, but become activated during
development along the antero-posterior axis according to
their positions in the cluster [30]. Previous work has
indicated that the chromatin that packages the Hoxb
genes in embryonic cells can be influenced by HDAC
inhibitors [31,32]. Here, we use them as a model system
to explore the relationship between changes in histone
modifications and transcription as genes switch from
silenced to active states.Figure 1 Valproic acid induces global histone hyperacetylation and H
showing changes in the indicated histone modifications after treatment of
acid (VPA), and at various timepoints after its removal (wash out). Staining
as a loading control (H3 C-term, bottom tracks). (B) Measurement of the flu
modifications over time (n = 3).Results
VPA causes global histone modification changes in ES
cells but has little effect on gene expression or
differentiation state
ES cells treated with 1 mM VPA for up to 8 h showed a
progressive increase in acetylation of H2B, H3 and H4
and in trimethylation of H3K4, all of which began to
level off after 2 to 4 h (Figure 1). The induced increases
were rapidly reversible, returning to pre-treatment
levels or below within less than 30 minutes of removal
of the inhibitor (Figure 1). This behaviour is consistent3K4 hypermethylation in embryonic stem cells. (A) Western blots
embryonic stem (ES) cells (CCE/R) for up to 8 h with 1 mM valproic
with an antibody to the unmodified H3 C-terminal domain was used
orescent secondary antibody signal quantifies changes in histone
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references therein).
The VPA treatment caused a several-fold drop in
transcripts from the pluripotency genes Nanog and
Klf4, a slight drop in expression of Oct4 (a marker of
undifferentiated cells) but no significant change in cMyc
(Figure 2A). OCT4 and KLF4 proteins were not affected
over the timescale of the experiment (Figure 2B; we were
unable to detect NANOG protein by western blotting).
Importantly, expression of these genes was restored
within 1 day of removal of VPA (Figure 2A). There was
a consistent change in morphology after 8 h in VPA,
with cells tending to become more flattened. However,
this change was not accompanied by loss of pluripotency,
as shown by alkaline phosphatase (AP) staining, and
morphology returned to normal following VPA removal
(Figure 2C). Thus, we find no evidence that treatment of
ES cells with VPA for up to 8 h permanently disturbs their
undifferentiated state. Over an 8-h treatment time, 1 mM
VPA did not detectably change the cells’ characteristic
cell cycle profile, with more than 60% of cells in S-phase
in both treated and untreated cultures (Figure 2D), nor
did it increase the number of dead or metabolically
inactive cells.
To compare global transcription levels in control and
VPA-treated ES cells, we used the NIA15K array,
comprising 15,247 unique oligo(dT)-primed cDNA clones
derived from 52,374 Expressed Sequence Tags (3′ ESTs),
mostly from early embryonic cDNA libraries [33]. The
NIA15K array is ideal for the accurate measurement
of gene expression levels in embryonic cells [34,35].
Two-colour (cy3/cy5) labelling was used to compare
VPA-treated and untreated samples. M-values, representing
the ratio between the cy3 and cy5 fluorescent signals,
from three independent experiments were tested for
statistical significance using P-values corrected using
the Benjamini False Discovery Rate (FDR) correction.
After 8 h in 1 mM VPA, 1,144 genes (7.5%) on the array
showed a significant change in transcription activity
(P ≤0.1 after FDR correction), of which 674 were up-
and 470 down-regulated. However, for many of these
genes the fold changes were small and when we applied
additional thresholds the number of genes showing
changes dropped rapidly. Thus, only 359 genes (2.4%)
changed between 1.5- and 2-fold (241 up-, 118 down-
regulated), and just 123 (0.8%) changed more than 2-fold
(95 up and 28 down). These results are summarised
in Figure 3A. Selected genes for which replicate micro-
array analyses consistently showed differing degrees of
VPA-dependent change in expression (Figure 3B),
were tested by RT-qPCR. Results were consistent with
both the direction and relative magnitude of change
detected by microarray analysis; examples are shown
in Figure 3C.Ontology analysis of this dataset, using DAVID
software, revealed several annotations to be significantly
over-represented amongst genes whose activities were
altered by VPA. The most significant are listed in
Additional file 1: Table S2. The highest scoring annotation
was Cytoskeleton and cytoskeleton-interacting proteins
(P = 5.13 × 10-5). Cell cycle (P = 6.76 × 10-4) and chromatin
organisation (P = 6.46 × 10-3) were also featured. The
effect on cytoskeleton-related genes is intriguing in light
of the morphological changes induced by VPA. However
the short timescale involved and the reversibility of the
effect makes it likely that morphological changes were
the result of a combined effect of altered acetylation of
cytoskeletal proteins and gene expression changes [36].
VPA-induced changes in transcription at specific genes
are not consistently linked to changes in histone
acetylation
To ask whether these expression changes were associated
with changes in histone modification at promoter or
intragenic regions, we used ChIP to test genes that showed
varying levels of expression change after VPA treatment.
Examples (Egr1,H1f0,Ndrg4, Nanog) are shown in Figure 4.
None of these genes showed any significant VPA-induced
change in H3K27me3, H4K8ac or H3K4me3 (Figure 4)
despite the global increase in the latter two modifications
induced by VPA (Figure 1). H3K9ac levels were more
variable, with occasional modest increases (1.5- to 2-fold)
at sites across Ndrg4 and H1f0 (Figure 4). However, for
this modification too, the ChIP results reflect neither the
global changes in histone modification, nor the changes in
transcript levels seen in response to VPA (Figures 1
and 3). This lack of correlation between HDACi-
induced global and local acetylation, and between
acetylation and transcription, is consistent with previous
results [20,22,37].
Hoxb genes show increased H3 acetylation following VPA
treatment, but this is associated with increased
transcription only at certain loci
We previously showed that treatment with VPA of cultured
mouse embryos at the 8-cell to morula stage, caused
increased acetylation and H3K4 methylation at Hoxb1
and Hoxb9, but not at other genes [32]. In ES cells,
we found that treatment with VPA caused a consistent
increase in H3K9 acetylation at all Hoxb promoter
regions, with the level of acetylation increasing from
2-h to 8-h exposure time (Additional file 2: Figure S1, A).
Thus, in contrast to its lack of effect on most other genes,
VPA increases promoter H3K9 acetylation across the
entire Hoxb cluster, including Hoxb13 located about 70 kb
from its nearest Hoxb neighbour, Hoxb9 (Additional file 2:
Figure S1, C). Subsequent experiments showed that VPA
increased H3K9 acetylation at upstream, promoter and
Figure 2 (See legend on next page.)
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Figure 2 Valproic acid reduces expression of selected pluripotency genes but does not trigger long-term changes in cell growth or
differentiation. (A) Embryonic stem (ES) cells (CCE/R) were treated for 8 h with 1 mM valproic acid (VPA) followed by culture for one or five days
in the absence of the drug (wash out, WO). The expression of four pluripotency-associated genes was quantified by real time-quantitative (RT-q)
PCR, relative to the expression of β-actin, in untreated, VPA-treated and WO cells. Error bars represent the standard error (SE) of the mean of
independent experiments (n = 3). To assess the significance of a change, two-tailed unpaired t-tests were performed using GraphPad software;
***P < 0.001. (B) Levels of OCT4 and KLF4 proteins were checked before (left lane) and after (right lane) VPA treatment by western blotting. A
measure of the secondary antibody fluorescent signal, normalised to the β-actin signal, allowed a quantitative representation of changes. Error
bars indicate SE from 3 independent experiments. (C) Light microscopy was used to assess the cell morphology at each timepoint (upper panels).
Alkaline phosphatase activity (red staining) was used as a marker of pluripotency (lower panels, pictures taken using 20× magnification). (D) ES
cells were stained with propidium iodide (PI) and analysed by flow cytometry to obtain the mean percentage of cells in each phase of the cell
cycle before and after VPA treatment and WO (n = 3).
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induced more modest (though sometimes statistically
significant) increases in H3K4me3 at these same regions
(Figure 5A; see also Additional file 2: Figure S1, B).
Surprisingly, H4K8ac was unchanged while increases in
H3K27ac were limited to Hoxb4 and Hoxb7 (Figure 5A).
As expected [38], all Hoxb genes showed relatively high
levels of H3K27me3, which decreased slightly (though not
significantly for any single gene) after VPA treatment
(Figure 5A).
In pre-implantation mouse embryos in culture, VPA-
induced increases in both histone acetylation and H3K4me3
were heritable through mitosis in the absence of the
inhibitor, at least until the blastocyst stage [32]. In
contrast, in ES cells the VPA-induced increases in
H3K9ac were consistently lost within 24 h of removal of
the inhibitor. A typical experiment is shown in Additional
file 2: Figure S2. It will be interesting to explore possible
reasons for the different behavior of pre-blastocyst
embryos and cultured cells (ES cells) derived from the
Inner Cell Mass of the blastocyst.
To ask whether VPA could change the expression of
ES cell Hoxb genes we tested two lines, CCE/R (feeder-
independent) and J1 (feeder-dependent and parent line
of the double knockout (dKO) cells used later) using
RT-qPCR. With the single exception of Hoxb2, transcript
levels before treatment were similar in the two lines.
The effect of VPA treatment was also very similar in the
two lines, with only Hoxb4 and Hoxb7 significantly affected,
each showing a 2- to 3-fold increase (Figure 6). In
untreated CCE/R cells, Hoxb4 and Hoxb7 showed the
highest levels of H3K4me3, H3K9ac and H3K27ac at
selected sites in their promoter regions and also showed the
strongest VPA-induced increases in H3K27ac (Figure 5).
In view of these findings, it is interesting to note that
of three genes showing strongly increased transcription
after VPA (Figure 3C), two showed relatively high levels
of H3K27me3 (H1f0, Egr1), while one (Ndrg4) did not
(Figure 4). Thus, Polycomb-mediated silencing is not a pre-
requisite for VPA-induced increases in either transcription
or H3K9ac and cannot, in itself, explain the characteristic
and unusual response of Hoxb genes to this inhibitor.Hoxb genes are all induced by retinoic acid in
differentiating ES cells but longer-term expression varies
from gene to gene
We have used the Hoxb gene cluster to explore the
relationship between induced changes in histone
modification and switching from a silent to an expressed
state. Induction of differentiation by removal of leukaemia
inhibitory factor (LIF) (day 0), and addition of retinoic
acid (RA, day 2), resulted in the rapid up-regulation of all
Hoxb genes (Figure 7). However, the activation progressed
differently depending on the Hoxb locus involved. For
Hoxb1, 3, 6 and 8, expression increased rapidly on day 3
and remained approximately constant, or declined (Hoxb1
only), whereas Hoxb2, 4, 5, 7 and 9 all increased slowly, to
reach maximum expression around day 8, the latest time
point examined. There was no clear correlation between
the timing of maximum RA-induced expression of
individual Hoxb genes and their position in the clus-
ter. Nor was there any correlation between the levels
of histone modification tested at Hoxb promoters
(Figure 5) and the longer-term progression of the
RA-induced increase in transcription. Following RA
treatment (day 2) there was by day 3 a several-fold
increase in H3K9ac at promoter-proximal and coding
regions of all Hoxb genes tested (Hoxb1, 2, 4, 5, 7 and 9).
Illustrative results are shown in Figure 8. In view of
previous results, it is significant that induction of ES
cell differentiation by LIF withdrawal increased neither
Hoxb transcription nor H3K9ac levels at Hoxb promoters
(Figures 7 and 8). Thus, the short-term effects of VPA on
H3K9ac at Hoxb promoters and Hoxb expression,
cannot be attributed to induction of differentiation in a
subpopulation of ES cells.
Loss of Polycomb components generally increases Hoxb
gene expression and modulates the transcriptional
response to VPA in a locus-specific manner
To test the role of Polycomb in silencing Hoxb in undif-
ferentiated ES cells, we measured expression of Hoxb
genes in an ES cell line in which both PRC1 and PRC2
were non-functional [39]. Total lack of expression of
Ring1b (PRC1) and Eed (PRC2) in these dKO cells was
Figure 3 Valproic acid treatment changes expression of only a small proportion of genes in embryonic stem cells. Embryonic stem (ES)
cells (CCE/R) were treated for 8 h with 1 mM valproic acid (VPA) and the NIA15K cDNA microarray was used to compare gene expression in
control and treated cells. The use of three biological replicates allowed statistical testing (t-tests) to classify genes by the level of significance
(P-value) of their expression change. (A) Genes for which the change in transcript level (up or down) had a P-value after FDR correction, equal to or less
than 0.1, and a mean change of at least 1.5-fold, were classed as up- or down-regulated, as indicated. The histogram shows the numbers of genes where
the significant fold change is 1.5- to 2.0-fold (light grey) or >2.0-fold (dark grey). (B) Heat map showing gene expression change in three replicate
experiments along with a list of representative genes showing different levels of change. (C) To validate microarray results, representative transcripts were
quantified by real time-quantitative (RT-q)PCR in untreated and VPA-treated cells. Error bars represent the standard error of the mean of independent
experiments (n = 3). To assess significance of a change, two-tailed unpaired t-tests were performed using the GraphPad software; *P <0.05.
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of Polycomb components in those cells led to a strong
diminution of the H3K27me3 mark, as expected, and a
corresponding increase in global H3K27ac (Additional
file 2: Figure S3).
Hoxb genes, showed a several-fold increase in expression
in dKO cells (Figure 9A), with the exception of Hoxb5,
whose activity remained very low, and possibly Hoxb1
(where the increase was not significant). However, even in
the absence of Polycomb, levels remained well below
those observed after differentiation and exposure to RA(Figure 7). As in wild-type cells, treatment of dKO cells
for 8 h with 1 mM VPA induced global hyperacetylation
of histones and a modest increase of H3K4me3
(Additional file 2: Figure S3). However, with the exception
of Hoxb1, VPA caused no further increase in the expression
of Hoxb genes over that induced by loss of Polycomb
(Figure 9B). Hoxb1 was a clear exception, showing a 4.5-
fold increase in expression after VPA treatment.
The comparatively weak activation of Hoxb1 in response
to Polycomb depletion (Figure 9A), its strong response
to VPA in Polycomb null cells (Figure 9B) and the
Figure 4 Valproic acid-induced changes in transcription at specific genes are not consistently linked to changes in histone acetylation.
Modified histones were assayed at selected regions of genes showing increased expression (H1f0, Egr1, Ndrg4), or decreased expression (Nanog)
in response to valproic acid (VPA). Chromatin was prepared from CCE/R embryonic stem (ES) cells before (white bars) and after (black bars) VPA
treatment (1 mM, 8 h) and immunoprecipitated with antibodies against H3K9ac, H3K4me3, H4K8ac and H3K27me3, as indicated. DNA extracted
from bound (B) and unbound (UB) fractions was analysed by real time-quantitative (RT-q)PCR using region-specific primers (Additional file 1:
Table S7 shows both the sequences and positions relative to the transcription start site of each primer pair). Relative enrichment in each
modification was calculated as the B/UB ratio; a region can be considered enriched in a particular modification if B/UB exceeds 1.0 (dashed lines).
Error bars represent the standard error of the mean of independent experiments (n = 2): apparent absence of error bars occurs where the error is
too low to be visible at this scale.
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differentiating cells over time (Figure 7), all suggest that
Hoxb1 is subject to a regulatory regime that differs from
other Hoxb genes. Hoxb1 is distinguished by its proximity
to two RA response elements (RAREs), DR2 and DR5,
which lie 1.5Kb and 6.5Kb respectively, 3′ of the Hoxb1
coding region. We find both RAREs in CCE/R ES cells are
strongly enriched in the silencing mark H3K27me3, with
below average levels of H3K27ac, H3K9ac, H4K8ac and
H3K4me3 (Figure 5C). VPA treatment caused no changes
in the modifications tested at DR5, but DR2 showed an
approximately 2-fold increase in H3K9ac and H3K27ac,
along with a small diminution of H3K27me3 (Figure 5C).These changes, though modest, may contribute to the
distinctive transcriptional responses of Hoxb1.
Discussion
ES cells treated with VPA showed dramatic global changes
in histone modification, including increased acetylation of
all histones and H3K4 methylation, but surprisingly
limited changes in both transcript levels and histone
modification levels at individual promoters. In line with
the limited transcriptional response, we found only very
occasional evidence for genes showing altered histone
acetylation or H3K4 methylation following growth in
VPA, even among those genes showing the strongest
Figure 5 Valproic acid changes acetylation of some histone lysines at Hoxb promoter regions. (A) Levels of H3K9ac, H3K4me3, H3K27me3,
H3K27ac and H4K8ac across Hoxb genes were assayed by chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) of chromatin from
embryonic stem (ES) cells, either treated with 1 mM valproic acid (VPA) for 8 h (black bars) or untreated (white bars). Regions with bound (B)/
unbound (UB) ratios >1.0 (dashed line) can be considered relatively enriched in that modification. Error bars represent the standard error of the
mean of independent experiments (n = 3 for H3K27ac, n = 2 for the remainder): apparent absence of error bars occurs where the error is too low
to be visible at this scale. (B) Positions of Hoxb primers (1.1, 1.2 et cetera.) are shown, along with the positions of the most upstream and
downstream primer bases, relative to the TSS (−451, +450 etc.). (C) Levels of histone modifications across the retinoic acid response elements DR2
and DR5 assayed by ChIP-qPCR of chromatin from ES cells, either treated with 1 mM VPA for 8 h (black bars) or untreated (white bars).
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global hypermodification and minimal local modification
changes is consistent with our recent studies on human
lymphoblastoid cell lines [22], and suggests that in ES
cells, as in other cell types, many genes are sheltered from
the global changes in histone modification induced by
environmental inhibitors. This may also help explain the
low frequency of VPA-induced changes in gene expression.
Following completion of the microarray experiments
presented here, Hezroni and colleagues [40] published
data showing limited transcriptional change following
treatment of ES cells with VPA. Comparison of our datawith the nearest equivalent set from Hezroni and
colleagues, shows a strong overlap, despite differences in
treatment time and concentration (0.5 mM VPA for 4 h vs
1 mM for 8 h). Of our 241 up-regulated (>1.5-fold) genes,
52 were classified as up-regulated by Hezroni et al. [40].
The overlap for down-regulated genes was less striking at
118 and 18 respectively. Genes in common are listed in
Additional file 1: Table S3. Ontology analysis (DAVID) of
these common genes showed that enrichment scores >1.3
and P-values <0.01 were restricted to the terms, steroid
metabolism/homeostasis, protein transport/localization
and negative regulation of differentiation/neurogenesis.
Figure 6 Valproic acid induces transcription of specific Hoxb
genes in undifferentiated embryonic stem cells. Two mouse
embryonic stem (ES) cell lines CCE/R (panel A, feeder-independent)
and J1 (panel B, feeder-dependent and the parent line of the Eed/
Ring1b double knockout (dKO) cells) were treated with valproic acid
(VPA) (1 mM, 8 h) and harvested, along with untreated controls, for
preparation of RNA and cDNA. Transcript levels from Hoxb1-9 were
determined by real time-quantitative (RT-q)PCR. Error bars show the
standard error of the mean of independent experiments (n = 3).
Two-tailed unpaired t-tests were used to assess significance of
changes; *P <0.05, **P <0.01.
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modification and local transcriptional effects has been
noted in ES cells depleted in DPY30, a key component
of the MLL2 histone methyltransferase complex [41].
Dpy30 −/− cells showed minimal transcription changes,
despite major global and local reductions in H3K4
methylation [41]. However, DPY30 depleted cells showed
reduction or absence of expression of lineage-specific
genes following RA treatment and compromised neuronal
differentiation [41].
In quiescent human CD4+ T-cells, hyperacetylation
induced by the inhibition of HDACs with a mixture of
butyrate and TSA, occurred on only a minority of genes,
primarily those that were transcriptionally active [21].Among silent genes, a subset of less than 15% was found
to be susceptible to hyperacetylation in the presence of
HDACi. The great majority of this subset were marked
by elevated levels of H3K4 methylation and could
therefore be categorised as bivalent, poised genes
[42,43]. Transcriptionally active genes are generally
enriched in H3K4 methylation, particularly at their
promoters [44], and it may be that levels of H3K4me3 are
a more important determinant of sensitivity to HDACi
than transcription per se. In contrast, Hezroni et al. [40]
found only modest local changes in H3K9ac in ES cells
treated with 0.5 mM VPA (less than 20% overall after 4 h
treatment); there was variation between genes but no
evidence that acetylation was selectively increased at
regions classed as bivalent [40].
Our results illustrate how the Hoxb genes in ES cells
are regulated by a combination of cluster-wide and
locus-specific mechanisms. Thus, all Hoxb genes are
kept in a silent state, at least in part, by Polycomb silencing
complexes, being marked by a blanket of the Polycomb-
associated histone modification H3K27me3 [45]. Similarly,
all Hoxb genes are activated when differentiating cells
are exposed to RA (see [46] and references therein).
Remarkably, there is evidence that a binding site for
RA receptor gamma in the Hoxa1 upstream enhancer
is a key player in cluster-wide activation of Hoxb genes
[46]. Locus-specific effects became apparent when the
time-course of the RA response was followed, with clear
differences in the times at which individual Hoxb genes
are maximally expressed, from day 3 to day 8 of differenti-
ation. In contrast to in vivo data [30,47], in ES cells grown
and RA-treated in culture, we found no clear correlation
between the timing of maximal expression (transcript
level) of individual Hoxb genes and their position in
the cluster. The clear-cut and consistent differences in
timing show that regulatory mechanisms acting at the
level of individual loci, or groups of loci, can moderate the
cluster-wide effect triggered by RA.
All Hoxb loci showed increased H3K9 acetylation in
the presence of the HDACi, VPA. VPA consistently
increased levels of H3K9ac at upstream, promoter and
coding regions across the entire Hoxb cluster. H3K27ac
and H3K4me3 both showed more modest, though
occasionally significant, VPA-induced increases. Perhaps
surprisingly, H4K8ac, a modification that shows a global
increase after VPA, remained unchanged at all Hoxb loci
tested. It is interesting that levels of H3K27me3 were
consistently lower across Hoxb genes in VPA-treated cells,
though the reductions were always small and statistically
insignificant for any single locus. The HDACi-induced
increase in H3K9ac at Hoxb loci shows that H3 acetate
groups are turning over at these loci, which must there-
fore contain both HDACs and histone acetyltransferases
(HATs). It will be interesting to identify these enzymes. In
Figure 7 The timing of Hoxb gene expression in mouse embryonic stem cells following induction of differentiation. Mouse embryonic
stem (ES) cells (CCE/R) were induced to differentiate by removal of the growth factor leukaemia inhibitory factor (LIF) and replating at day 0,
followed by addition of retinoic acid (RA, 1 μM) at day 2. RNA and cDNA were prepared from cell pellets at day 0 and daily thereafter and
transcript levels from individual Hoxb genes (Hoxb 1 to 9) were determined by real time-quantitative (RT-q)PCR. At each timepoint, expression was
calculated as a percentage of the highest value in the untreated sample. Error bars represent the standard error of the mean of independent
experiments (n = 3).
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induced hyperacetylation have not always been found
to be rich in HDACs, leading to the suggestion that
the association of HDACs with such regions was transient
and unstable [21]. As the specificity of HDACs for
particular histone types tends to be low [9,48], it is likely
that the absence of VPA-induced acetylation of certain H3
and H4 lysines across Hoxb loci reflects the absence of
catalytically-active HATs of the necessary specificity,
rather than variations in HDAC levels or types. A strong
overlap has been noted in mouse ES cells between
peaks of H3K9ac and the HAT p300 [40]. However,
the significance of this is uncertain and much remains
to be learned about the in vivo specificity of the various
HAT complexes. Knock-out experiments have shown thatdepletion of CBP/p300 specifically reduces acetylation at
H3K18 and H3K27, while GCN5 depletion selectively
reduces H3K9ac [49].
It is interesting that only Hoxb4 and Hoxb7 showed a
significant increase in transcription following VPA treat-
ment of wild-type ES cells. As VPA treatment increased
H3K9ac across Hoxb4 and Hoxb7, and across Hoxb1, 2
and 5, where transcription does not change, we can
conclude that increased H3K9ac levels are not caused
by increased transcription, nor are they sufficient, in
themselves, to trigger transcription in all Hoxb genes.
Of the modifications tested, only H3K27ac showed
VPA-induced increases selectively at Hoxb4 and 7,
thus correlating with changes in transcription. It has
been suggested previously that H3K27ac might exert
Figure 8 Treatment of differentiating embryonic stem cells with retinoic acid increases H3K9ac at Hoxb genes. Chromatin
immunoprecipitation-quantitative PCR (ChIP-qPCR) was used to investigate H3K9ac levels at two or three regions across four Hoxb genes, as
indicated, in differentiating embryonic stem (ES) cells (CCE/R) before and after treatment with retinoic acid (RA). Leukaemia inhibitory factor (LIF)
was removed at d0 (0 h) and RA added at d2. Location of the primer pairs used is shown in Figure 5B. Data are displayed as the enrichment of
the Hoxb sequences in the bound relative to the unbound (B/UB) sample for each timepoint. Error bars represent the standard error of the mean
of independent experiments (n = 2).
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effects of, H3K27me3 [50], and such a process is consistent
with our data. The results so far also indicate that
increased transcription of Hoxb genes in the presence of
continued Polycomb repressor complex (PRC) silencing
can only be induced at loci that are pre-marked by higher
than average levels of H3K4me3, H3K9ac and H3K27ac.
Perhaps these modifications are part of a permissive
chromatin environment that facilitates VPA-induced
transcription. Our results show that a high level of
H3K4me3 is not, in itself, necessary for the VPA-sensitive
chromatin state at all Hoxb loci, though it may play a
locus-specific role, perhaps in facilitating the up-regulation
of transcription in response to HDACi [21].
As expected, the absence of functional PRC complexes in
Eed/Ring1b dKO cells led to increased Hoxb transcription.
However, the increase varied from 8-fold and highly
significant for Hoxb7, to small and insignificant for
Hoxb1 and Hoxb5. Interestingly, removal of Polycomb
did not make the Hoxb genes more susceptible to the
effects of HDACi-induced acetylation. With the exception
of Hoxb1, treatment of dKO cells with VPA caused little
further increase in Hoxb expression. Hoxb1, for which
there was a relatively small (not significant) increase
in transcription following PRC inactivation, showed a
robust increase when dKO cells were treated with VPA.
Collectively, these findings suggest that increased H3K9ac
acetylation (and perhaps acetylation at other lysines
not yet tested) induced by VPA can partially overridePRC-mediated silencing of some Hoxb genes (particularly
Hoxb4 and Hoxb7), but causes no further increase in
transcription in the absence of PRC. Thus, with the ex-
ception of Hoxb1, an increase in activating marks even
in the absence of Polycomb-associated silencing, does not,
in itself, induce transcription. The results emphasize that
Hoxb1 has regulatory features that distinguish it from
other genes in the Hoxb cluster. It may be significant that
chromatin opening, perhaps progressing 3′ to 5′ through
the cluster, has been shown to be important for Hox
gene activation [31,51]. If Hoxb1 chromatin is selectively
decondensed in PRC-deficient cells, it could be more
sensitive to VPA-induced acetylation, perhaps because
this facilitates the transient attachment of HATs and
HDACs [21].
Gene silencing is a multi-layered process, involving the
combinatorial actions of histone and DNA modifications,
chromatin condensation, DNA binding proteins, small
RNAs and the intra-nuclear location of genes and gene
clusters. Gene activation involves stripping away some or
all of these silencing components and may not be an all or
nothing process. As we have seen, the Hoxb genes can be
significantly up-regulated by treatment with VPA, or by
removal of the Polycomb complex, though the level of
activation is far below that seen following induction of
differentiation and treatment with RA. In contrast, most
genes in ES cells are insensitive to VPA treatment, and
even within the Hoxb cluster, the response of Hoxb1 sets
it apart from the other Hoxb genes. Definitive conclusions
Figure 9 Knockout of Eed/Ring1b increases expression of Hoxb genes but only Hoxb1 responds additionally to valproic acid. (A)
Transcript levels of Hoxb genes were quantified by real time-quantitative (RT-q)PCR in wild-type embryonic stem (ES) cells (J1 line) and in J1 cells
in which two genes encoding Polycomb proteins (Eed; Ring1b) had been knocked out (dKO cells). Light grey bars show the expression levels in
wild-type J1 cells, and dark grey bars represent expression in dKO cells. (B) dKO cells were treated for 8 h with valproic acid (VPA) (1 mM). Hoxb
transcript levels in treated and untreated cells were assayed by RT-qPCR. Light grey bars represent untreated dKO cells, dark grey bars show data
for VPA-treated cells. For both panels error bars represent the standard error of the mean of independent experiments (n = 3). Two-tailed
unpaired t-tests were used to assess the significance of differences; *P <0.05, **P <0.01.
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difficult by the wide range of HDAC substrates, including
both histones and non-histone proteins, but of the modifi-
cations tested, H3K9ac and H3K27ac are associated in
both general and locus-specific ways with Hoxb regulation.
These related modifications could provide both a context
and the final trigger by which VPA activates Hoxb
expression, and it is important now to define the
regulatory pathways by which they are put in place and
through which they operate.
Conclusions
The HDACi, valproic acid, induces global histone hyper-
acetylation and increased H3K4 methylation in mouse
ES cells, but significantly alters the expression of only a
small proportion of genes, of which approximately one
third are down-regulated.There is no correlation between changes in expression
and levels of H3K9ac, H4K8ac or H3K4me3 at gene
promoters, which overall show little sign of VPA-induced
change in histone modifications. It seems that most genes
in mouse ES cells are sheltered from the global increases
in histone modification induced by VPA.
Hoxb genes were exceptional in showing consistently
increased H3K9ac at promoter and intragenic regions in
cells exposed to VPA. H3K27ac and H3K4me3 showed
smaller increases at only some Hoxb loci while H4K8ac
was unaffected. VPA consistently caused small reductions
in H3K27me3, though these never achieved statistical
significance for any one locus. Only Hoxb4 and Hoxb7
showed significantly increased transcription after VPA
treatment. These two loci have the highest levels of
H3K9ac, H3K27ac and H3K4me3 in untreated cells and
show strong increases in acetylation in response to VPA.
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Hoxb genes several-fold, with the exception of Hoxb1 (only
weakly activated) and Hoxb5, which remained essentially
silent. Uniquely, Hoxb1 activity in PRC-negative cells
was increased several-fold by VPA. Thus, Hoxb genes
respond to VPA in a Polycomb-dependent and locus-
specific manner.
RA increased transcription of all Hoxb genes within 24 h,
with an accompanying increase in H3K9ac, but expression
thereafter, up to day 8, varied between Hoxb loci. In
differentiating ES cells there is no clear relationship
between the change in Hoxb expression over time and 3′
to 5′ position within the cluster.
Control of Hoxb genes is multilayered. Both PRC-
mediated silencing, with high levels of H3K27me3, and
RA activation, affect all Hox genes in the cluster. However,
these overall control mechanisms are modulated in differ-
ent ways at individual Hoxb loci. H3K9ac, H3K27ac and
H3K4me3 may all help provide aVPA-responsive chromatin
environment at specific Hoxb loci, but H4K8ac seems not
to be involved.
Methods
Primary cells and cell culture
The male mouse feeder-independent 129/Sv-derived ES
cell line, CCE/R [52], was grown on 0.1% gelatin-coated
flasks and 129S4/SvJae-derived ES cell line, J1, and
the Eed/Ring1B dKO, PRC1/PRC2-deficient) daughter
cell line were grown on mitotically inactivated mouse
embryonic fibroblast (MEF) feeder cells [39]. All ES
cell lines were cultured in DMEM supplemented with
20% foetal calf serum, 1× penicillin/streptomycin, 1×
L-glutamine, 1× non-essential amino acids, 0.25% 2-
mercaptoethanol and 1U/μl ESGRO (Millipore, Watford,
UK). All supplies were sourced from Invitrogen (Paisley,
UK) unless otherwise noted.
For RA-induced differentiation, ES cells were plated
on non-adherent plastic dishes in ES cell media minus
ESGRO with addition of 1μM all-trans-RA on day 2 of
differentiation [31]. Cell viability was assessed by Trypan
Blue staining and by the MTS assay (Promega, Southamp-
ton, UK), a calorimetric assay to detect metabolically
active cells (used according to the manufacturer’s instruc-
tions). ES pluripotency was tested by AP staining of
undifferentiated fixed adherent cells [53,54]. Cell cycle
analysis was performed using PI (10 μg/ml) staining in
the presence of RNaseA (200 mg/ml) using a FACScan
flow cytometer (BD FACSCalibur™, Becton Dickinson,
Oxford, UK) and analysed using WinMDi 2.9 and
Cylchred software.
Antibodies
Rabbit polyclonal antisera to H4K8ac, H3K9ac, H3K4me3
and H2BK12/15 ac were raised in-house by immunisationwith synthetic peptides conjugated to ovalbumin as
previously described [55]. Sources of other antisera
are shown in Additional file 1: Table S4. Specificities
were assayed by inhibition ELISA for all in-house and
commercial antisera [55] and checked by western blotting.
Protein analysis
Histones were extracted from ES cells by acid extraction
and analysed by electrophoresis in 15% SDS-polyacrylamide
gels and western blotting as previously described [1]
Protein loading was tested by Ponceau S staining before
proteins were probed with appropriate primary antibodies.
Primary antibody binding was detected by fluorescent
tagged anti-rabbit IgG secondary antibodies (Rockland)
and detected by scanning (Odyssey system; LI-COR,
Cambridge, UK).
Native chromatin immunoprecipitation (NChIP)
Immunoprecipitation of native chromatin was performed
based on the method described previously [56] and DNA
was analysed using qPCR. Briefly, cells were lysed to
release nuclei prior to micrococcal nuclease digestion.
The amount of micrococcal nuclease added and digestion
time were adjusted to obtain a mix of mono- and short
oligo-nucleosomes, optimal for immunoprecipitation [56].
Digested chromatin was immunoprecipitated and bound
(B) and unbound (UB) fractions were separated. DNA
from B and UB fractions was isolated and analysed
by qPCR using region specific primers. Sequences of
all ChIP-qPCR primers are listed in Additional file 1:
Tables S5-S7.
Gene expression analysis
Total RNA was extracted from cells using the RNeasy
mini kit (Qiagen, Crawley, UK) according to the manu-
facturer’s instruction. An on-column DNase digestion
was performed during the extraction in order to yield a
pure RNA fraction (RNase-Free DNase Set, Qiagen).
cDNA was prepared using the RT-Superscript-III Kit
(Invitrogen) according to manufacturer’s instructions.
cDNA was then analysed using qPCR or microarrays.
For each RT-qPCR assay, 50 ng of cDNA were mixed
with 5μl of SYBR green Mix (Qiagen), forward and
reverse primers (0.4 μM each) and RNase-free water in a
final volume of 10 μl. The PCR reaction was run on the
ABI 7900HT system (95°C for 10 minutes; 40 cycles of
94°C for 15 s, primer set-specific annealing temperature
for 30 s 72°C for 30 s, with a final denaturation step 95°
C for 15 s, 60°C for 15 s, 95°C for 15 s). Standard curves
made from serial dilutions of cDNA allowed relative
quantification. Sequences of all primers and Tm used for
qPCR are listed in Additional file 1: Table S8.
For microarray expression analysis we used the NIA
15 K mouse cDNA array [33] as previously described
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two different fluorochromes, cy3 and cy5 (Amersham,
Little Chalfont, UK) using a Bioprime Labelling kit
(Invitrogen). Following their purification (PCR purification
Kit; Qiagen), equal amounts of probes were combined and
precipitated before hybridization onto slides at 42°C
for 20 h. Slides were scanned using GenePix 4000A
scanner. Spot alignment was checked automatically
and then manually using GenePix software. Data were
normalised using the DNMAD web-software. T-tests
were performed on total M-values using biological
triplicates for each condition and standard P-values
were then corrected by the Benjamini-Hochberg FDR
method using the statistical environment “R”. Finally,
genes with associated FDR less than 10% were considered
statistically significant and selected for further analysis.
Original microarray data files are available through the
GEO database [GSE45610].
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inhibitors. Table S2. Functional annotation of genes whose expression is
altered by VPA. Table S3. List of genes whose expression is altered by
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Table S4. Source of antibodies. Table S5. ChIP-qPCR primers, Hoxb1-13
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Table S7. ChIP-qPCR primers, non-Hox genes. Table S8. RT-qPCR
expression primers.
Additional file 2: Figures S1-S5. Figure S1. Chromatin
immunoprecipitation for H3K9ac, H3K4me3 at Hoxb promoters after 0, 2
and 8 h in valproic acid (VPA). Figure S2. Non-persistence of H3K9ac at
Hoxb loci after removal of valproic acid (VPA). Figure S3, characterisation
of Eed/Ring1b double knockout (dKO) cells.
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